Julia E Maxson
Overview
Explore the profile of Julia E Maxson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Darmusey L, Bagley A, Nguyen T, Carlson H, Blaylock H, Shrestha S, et al.
Blood Adv
. 2025 Jan;
PMID: 39777477
Mutations in the epigenetic regulator Additional Sex Combs-Like 1 (ASXL1) are frequently observed in chronic neutrophilic leukemia (CNL). CNL is a myeloproliferative neoplasm (MPN) driven by activating mutations in the...
2.
Kong G, Nguyen T, Rosales W, Panikar A, Cheney J, Lusardi T, et al.
BMC Bioinformatics
. 2024 Apr;
25(1):142.
PMID: 38566005
Background: The rapid advancement of new genomic sequencing technology has enabled the development of multi-omic single-cell sequencing assays. These assays profile multiple modalities in the same cell and can often...
3.
Hollander M, Malaker S, Riley N, Perez I, Abney N, Gray M, et al.
J Biol Chem
. 2023 Apr;
299(6):104755.
PMID: 37116708
The colony-stimulating factor 3 receptor (CSF3R) controls the growth of neutrophils, the most abundant type of white blood cell. In healthy neutrophils, signaling is dependent on CSF3R binding to its...
4.
Yashar W, Curtiss B, Coleman D, VanCampen J, Kong G, Macaraeg J, et al.
Mol Cancer Res
. 2023 Mar;
21(7):631-647.
PMID: 36976323
Implications: This work establishes the synergistic efficacy of combined FLT3 and LSD1 inhibition in FLT3-ITD AML by disrupting STAT5 and GFI1 binding at the MYC blood-specific superenhancer complex.
5.
RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development
Carratt S, Kong G, Coblentz C, Schonrock Z, Maloney L, Weeder B, et al.
Leukemia
. 2023 Mar;
37(5):1141-1146.
PMID: 36894620
No abstract available.
6.
Maniaci B, Chung J, Sanz-Altamira P, DeAngelo D, Maxson J
Haematologica
. 2022 Dec;
108(7):1945-1950.
PMID: 36579444
No abstract available.
7.
Braun T, Estabrook J, Schonrock Z, Curtiss B, Darmusey L, Macaraeg J, et al.
Leukemia
. 2022 Dec;
37(2):478-487.
PMID: 36526735
Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis....
8.
Bottomly D, Long N, Schultz A, Kurtz S, Tognon C, Johnson K, et al.
Cancer Cell
. 2022 Jul;
40(8):850-864.e9.
PMID: 35868306
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large...
9.
Carratt S, Braun T, Coblentz C, Schonrock Z, Callahan R, Curtiss B, et al.
Leukemia
. 2022 Jul;
36(8):2149.
PMID: 35794242
No abstract available.
10.
Yashar W, Kong G, VanCampen J, Curtiss B, Coleman D, Carbone L, et al.
Genome Biol
. 2022 Jul;
23(1):144.
PMID: 35788238
Genome-wide mapping of histone modifications is critical to understanding transcriptional regulation. CUT&Tag is a new method for profiling histone modifications, offering improved sensitivity and decreased cost compared with ChIP-seq. Here,...